Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG and Gemcitabine in BCG-Relapsing NMIBC
NCT04179162Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2019
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine in non-muscle-invasive bladder cancer (NMIBC), sponsored by Memorial Sloan Kettering Cancer Center. Started Nov 2019; status: active, not recruiting.
02
Drugs
gemcitabine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT04179162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04179162.